Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients
Autore:
Montejo, AL; Llorca, G; Izquierdo, JA; Rico-Villademoros, F;
Indirizzi:
Biometr Spain, Madrid, Spain Biometr Spain Madrid SpainBiometr Spain, Madrid, Spain Univ Salamanca, Sch Med, Psychiat Teaching Area, Univ Hosp Salamanca, E-37008 Salamanca, Spain Univ Salamanca Salamanca Spain E-37008 lamanca, E-37008 Salamanca, Spain
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
, volume: 62, anno: 2001, supplemento:, 3
pagine: 10 - 21
SICI:
0160-6689(2001)62:<10:IOSDAW>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; MAOI-INDUCED ANORGASMIA; PREMATURE EJACULATION; INCREASED LIBIDO; FLUOXETINE USE; PAROXETINE; DEPRESSION; MIRTAZAPINE; STIMULATION; FLUVOXAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Montejo, AL Ctr Salud Alamedilla, Serv Psiquiatria, Av Comuneros 27, Salamanca 37003, Spain Ctr Salud Alamedilla Av Comuneros 27 Salamanca Spain 37003 in
Citazione:
A.L. Montejo et al., "Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients", J CLIN PSY, 62, 2001, pp. 10-21

Abstract

Background: Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), venlafaxine, and clomipramine, are frequently associated with sexual dysfunction. Other antidepressants (nefazodone, mirtazapine, bupropion, amineptine, and moclobemide) with different mechanisms of action seemto have fewer sexual side effects. The incidence of sexual dysfunction is underestimated, and the use of a specific questionnaire is needed. Method: The authors analyzed the incidence of antidepressant-related sexual dysfunction in a multicenter, prospective, open-label study carried out by the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The group collected data from April 1995 to February 2000 on patients with previously normal sexual function who were bring treated with antidepressants alone or antidepressants plus benzodiazepines. One thousand twenty-twooutpatients (610 women, 412 men, mean age = 39.8 +/- 11.3 years) were interviewed using the Psychotropic-Related Sexual Dysfunction Questionnaire, which includes questions about libido, orgasm, ejaculation, erectile function, and general sexual satisfaction. Results: The overall incidence of sexualdysfunction was 59.1% (604/1022) when all antidepressants were considered as a whole. There were relevant differences when the incidence of any type of sexual dysfunction was compared among different drugs: fluoxetine, 57.7%(161/279); sertraline, 62.9% (100/159); fluvoxamine, 62.3% (48/77); paroxetine, 70.7% (147/208); citalopram, 72.7% (48/66); venlafaxine, 67.3% (37/55); mirtazapine, 24.4% (12/49); nefazodone, 8% (4/50); amineptine, 6.9% (2/29); and moclobemide, 3.9% (1/26). Men had a higher frequency of sexual dysfunction (62.4%) than women (56.9%), although women had higher severity. About 40% of patients showed low tolerance of their sexual dysfunction. Conclusion: The incidence of sexual dysfunction with SSRIs and venlafaxine is high, ranging from 58% to 73%, as compared with serotonin-2 (5-HT2) blockers (nefazodone and mirtazapine), moclobemide, and amineptine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 08:30:10